180.56

0.70% 1.25

After Hours: 180.56

Charles River Laboratories International Inc (CRL)

Overview News Price History Option Chain Financials Discussions Forecast

Charles River Laboratories International Inc stock is traded at $180.56, with a volume of 976.33K. It is up +0.70% in the last 24 hours and up +16.15% over the past month. Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Previous Close:

$179.31

Open:

$180.8

24h Volume:

976.33K

Relative Volume:

0.99

Market Cap:

$8.91B

Revenue:

$4.02B

Net Income/Loss:

$-142.16M

P/E Ratio:

-61.08

EPS:

-2.9563

Net Cash Flow:

$518.49M

1W Performance:

+3.14%

1M Performance:

+16.15%

6M Performance:

+5.76%

1Y Performance:

+70.47%

1-Day Range:

$177.38

$184.61

1-Week Range:

$170.20

$184.61

52-Week Range:

$99.80

$228.88

Charles River Laboratories International Inc Stock (CRL) Company Profile

Name

Charles River Laboratories International Inc

Sector

Healthcare (1112)

Industry

Diagnostics & Research (52)

Phone

781-222-6000

Address

251 BALLARDVALE ST, WILMINGTON, MA

Employee

19,700

Twitter

@criverlabs

Next Earnings Date

2024-11-06

Latest SEC Filings

CRL's Discussions on Twitter

Compare CRL vs TMO, DHR, IDXX, A, WAT

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRL Charles River Laboratories International Inc	180.56	8.85B	4.02B	-142.16M	518.49M	-2.9563
TMO Thermo Fisher Scientific Inc	531.67	195.93B	44.56B	6.72B	6.29B	17.74
DHR Danaher Corp	198.14	140.56B	24.57B	3.60B	5.26B	5.051
IDXX Idexx Laboratories Inc	580.76	46.39B	4.30B	1.06B	1.04B	13.08
A Agilent Technologies Inc	119.77	34.02B	7.07B	1.29B	993.00M	4.5355
WAT Waters Corp	326.20	32.49B	3.17B	642.63M	516.49M	10.77

Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-15-25	Upgrade	BofA Securities	Neutral → Buy
Nov-17-25	Upgrade	Argus	Hold → Buy
Nov-06-25	Upgrade	Robert W. Baird	Neutral → Outperform
Oct-06-25	Upgrade	William Blair	Mkt Perform → Outperform
Oct-02-25	Upgrade	Barclays	Equal Weight → Overweight
Sep-09-25	Upgrade	Jefferies	Hold → Buy
Jul-09-25	Upgrade	Citigroup	Neutral → Buy
May-23-25	Upgrade	Redburn Atlantic	Neutral → Buy
May-14-25	Upgrade	TD Cowen	Hold → Buy
May-08-25	Upgrade	Evercore ISI	In-line → Outperform
Mar-21-25	Downgrade	Goldman	Buy → Neutral
Mar-04-25	Upgrade	Citigroup	Sell → Neutral
Mar-03-25	Upgrade	Redburn Atlantic	Sell → Neutral
Jan-22-25	Downgrade	William Blair	Outperform → Mkt Perform
Jan-17-25	Downgrade	UBS	Buy → Neutral
Nov-18-24	Downgrade	CLSA	Hold → Underperform
Nov-07-24	Upgrade	CLSA	Underperform → Hold
Oct-23-24	Initiated	CLSA	Underperform
Oct-14-24	Initiated	Redburn Atlantic	Sell
Oct-07-24	Downgrade	Evercore ISI	Outperform → In-line
Oct-02-24	Downgrade	BofA Securities	Buy → Neutral
Oct-01-24	Downgrade	Citigroup	Neutral → Sell
Aug-08-24	Downgrade	JP Morgan	Overweight → Neutral
Aug-08-24	Downgrade	Robert W. Baird	Outperform → Neutral
Jun-28-24	Downgrade	Argus	Buy → Hold
Jun-07-24	Initiated	Mizuho	Neutral
Jun-06-24	Initiated	Goldman	Buy
Feb-15-24	Downgrade	Guggenheim	Buy → Neutral
Sep-13-23	Initiated	TD Cowen	Market Perform
Jul-10-23	Downgrade	Citigroup	Buy → Neutral
Feb-23-23	Upgrade	Guggenheim	Neutral → Buy
Jan-12-23	Downgrade	Jefferies	Buy → Hold
Sep-30-22	Upgrade	Jefferies	Hold → Buy
Aug-25-22	Initiated	Credit Suisse	Outperform
Aug-04-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
May-24-22	Initiated	Guggenheim	Neutral
Apr-25-22	Downgrade	Jefferies	Buy → Hold
Apr-07-22	Initiated	Stephens	Overweight
Feb-17-22	Reiterated	BofA Securities	Buy
Feb-17-22	Upgrade	Citigroup	Neutral → Buy
Feb-17-22	Reiterated	Deutsche Bank	Buy
Feb-17-22	Reiterated	Morgan Stanley	Overweight
Feb-17-22	Reiterated	UBS	Buy
Aug-05-21	Resumed	Credit Suisse	Neutral
Dec-16-20	Downgrade	Citigroup	Buy → Neutral
Sep-10-20	Upgrade	Jefferies	Hold → Buy
Jul-01-20	Upgrade	BofA Securities	Neutral → Buy
May-13-20	Upgrade	UBS	Neutral → Buy
Apr-21-20	Downgrade	Jefferies	Buy → Hold
Mar-27-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-02-20	Initiated	Deutsche Bank	Buy
Feb-18-20	Upgrade	Wolfe Research	Peer Perform → Outperform
Jan-10-20	Upgrade	Goldman	Neutral → Buy
Jan-08-20	Initiated	Wells Fargo	Overweight
Jan-07-20	Initiated	Citigroup	Buy
Oct-18-19	Downgrade	BofA/Merrill	Buy → Neutral
Jun-10-19	Initiated	SVB Leerink	Outperform
Apr-30-19	Resumed	Evercore ISI	Outperform
Dec-14-18	Initiated	Deutsche Bank	Buy
Oct-09-18	Initiated	UBS	Neutral
Aug-23-18	Upgrade	Raymond James	Mkt Perform → Outperform
Jul-17-18	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Jun-15-18	Upgrade	KeyBanc Capital Mkts	Sector Weight → Overweight
Feb-14-18	Upgrade	SunTrust	Hold → Buy

View All

Charles River Laboratories International Inc Stock (CRL) Latest News

05:47 AM

Charles River gains new outperform at RBC despite NAMs related disruption - MSN

05:47 AM

Apr 14, 2026

Charles River stock gains new Outperform at RBC (CRL:NYSE) - Seeking Alpha

Apr 14, 2026

Drug Development Services Market Research Report 2026: $50+ Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F - GlobeNewswire Inc.

Apr 14, 2026

Apr 13, 2026

Assessing Charles River Laboratories (CRL) Valuation After Recent Share Price Rebound - simplywall.st

Apr 13, 2026

RBC Capital initiates Charles River Labs stock at Outperform By Investing.com - Investing.com India

Apr 13, 2026

Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch

Apr 13, 2026

Apr 11, 2026

Does Charles River’s NSG BioLabs Tie-Up Reshape the Bull Case For Charles River Laboratories (CRL)? - Sahm

Apr 11, 2026

Charles River Laboratories Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo

Apr 11, 2026

Apr 10, 2026

Q3 2025 Charles River Laboratories International Inc Earnings Call Transcript - GuruFocus

Apr 10, 2026

Charles River Laboratories International (CRL) Positioned to Benefit from Preclinical Research Activity and Biotech Funding Recovery - insidermonkey.com

Apr 10, 2026

Charles River, American Heart Association Partner to Advance Cardiovascular Health Awareness - Contract Pharma

Apr 10, 2026

Charles River Labs stock: Margin Boost from Divestitures Signals Buy Opportunity - AD HOC NEWS

Apr 10, 2026

Apr 09, 2026

Charles River Advances Cardiovascular Health Awareness Through Support of the American Heart Associa - PharmiWeb.com

Apr 09, 2026

Charles River Advances Cardiovascular Health Awareness Through Support of the American Heart Association - The National Law Review

Apr 09, 2026

Charles River Labs stock: New Asia partnership signals growth potential - AD HOC NEWS

Apr 09, 2026

Apr 08, 2026

Charles River Labs (NYSE: CRL) CFO files Form 3 reporting zero stock ownership - Stock Titan

Apr 08, 2026

Charles River (CRL) Added to Tactical Outperform List by Evercore ISI - GuruFocus

Apr 08, 2026